Reduction of elevated IGF-1 levels in coincident amyotrophic lateral sclerosis and acromegaly.
We report a patient presenting with ALS in whom acromegaly was later confirmed. Insulin-like growth factor-1 (IGF-1) has been tried in the treatment of ALS and despite equivocal results from clinical trials, efforts have continued to try to harness the significant positive effects on motor neuron growth observed in vitro and in survival of mouse models of the disease. One subsequent study has reported an association between higher circulating serum IGF-1 levels and longer disease duration in ALS patients. Concern therefore arose in our case that treatment of the acromegaly with a somatostatin analogue might adversely affect the natural course of his ALS through lowering of potentially beneficial IGF-1 levels. Through clinical observation and prognostic modelling we suggest that this concern was unfounded. The potential interaction of these two rarely coincident disorders in our patient is discussed.
Pereira
Erlick A C
EA
University of Oxford Department of Clinical Neurology, John Radcliffe Hospital, UK.
Turner
Martin R
MR
Wass
John A H
JA
Talbot
Kevin
K
D000172:Acromegaly / Q000097:blood / Q000150:complications / Q000188:drug therapy; D000690:Amyotrophic Lateral Sclerosis / Q000097:blood* / Q000150:complications*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017809:Fatal Outcome; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I